CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 76 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2020. The put-call ratio across all filers is 0.27 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $16 | -97.0% | 491 | -95.9% | 0.00% | -100.0% |
| Q4 2022 | $539 | -99.8% | 12,102 | +35.7% | 0.00% | – |
| Q3 2022 | $250,000 | -43.9% | 8,916 | -46.1% | 0.00% | – |
| Q2 2022 | $446,000 | +7.0% | 16,546 | +35.0% | 0.00% | – |
| Q1 2022 | $417,000 | -16.8% | 12,252 | -5.7% | 0.00% | -100.0% |
| Q4 2021 | $501,000 | -60.6% | 12,990 | -64.8% | 0.00% | 0.0% |
| Q3 2021 | $1,270,000 | +2.4% | 36,911 | -0.5% | 0.00% | 0.0% |
| Q2 2021 | $1,240,000 | +2284.6% | 37,111 | +1357.6% | 0.00% | – |
| Q1 2021 | $52,000 | -89.5% | 2,546 | -91.0% | 0.00% | -100.0% |
| Q4 2020 | $493,000 | +94.9% | 28,144 | +65.0% | 0.00% | – |
| Q3 2020 | $253,000 | -68.9% | 17,062 | -72.7% | 0.00% | -100.0% |
| Q2 2020 | $813,000 | +2610.0% | 62,592 | +356.7% | 0.00% | – |
| Q4 2019 | $30,000 | +275.0% | 13,705 | +227.6% | 0.00% | – |
| Q3 2019 | $8,000 | -46.7% | 4,183 | -27.4% | 0.00% | – |
| Q2 2019 | $15,000 | +275.0% | 5,765 | +596.3% | 0.00% | – |
| Q1 2019 | $4,000 | – | 828 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |